Takeda has announced the commencement of a phase III clinical study of a promising new treatment for prostate cancer.
In association with Millennium, its oncology-focused subsidiary, the company will conduct a global trial that will gauge the efficacy of TAK-700 with prednisone among chemotherapy-naive metastatic castration-resistant prostate cancer patients.
The non-steroidal androgen synthesis inhibitor has shown efficacy in preclinical studies by blocking a key enzyme in the testes and adrenal glands, with Takeda hoping it will deliver benefits in overall and progression-free survival rates.
In addition, a second phase III study, which will assess TAK-700 among patients that have progressed during or following docetaxel-based therapy, will open enrolment later in 2010.
Dr Nancy Simonian, chief medical officer at Millennium, said: "Our hope is that this trial will demonstrate strong levels of efficacy that address the unmet medical needs in advanced prostate cancer."
Last month, Takeda submitted an application to the European Medicines Agency for approval of azilsartan medoxomil, a new treatment for essential hypertension.